BEVERLY HILLS, Calif., March 31, 2020 /PRNewswire-PRWeb/ -- Skinuva™ is proud to release Skinuva™ Brite, its second product in its revolutionary growth-factor based topical formulation portfolio. Skinuva™ Brite is non-hydroquinone topical formulation with tailored ingredients including growth factors to help improve hyperpigmentation. Similar to the science utilized in creating Skinuva™ Scar, Skinuva™ Brite uses the latest growth factor technology to provide a safe and effective daily use product for the treatment of hyperpigmentation.
"There has been a recent consumer demand to provide safe and effective non-hydroquinone topical formulations in the treatment of hyperpigmentation," states CEO and Founder Dr. Christopher Zoumalan, who also practices as a Beverly Hills Oculoplastic Surgeon. "We wanted to use our clinical knowledge in developing the most advanced product possible for hyperpigmentation on the market, while clinically testing our product at the highest standards," further states Dr. Christopher Zoumalan.
Skinuva™ Brite has been extensively tested and found to be safe and effective in improving hyperpigmentation. Types of hyperpigmentation include melasma, post inflammatory hyperpigmentation, under eye hyperpigmentation and sun spots. Our recent clinical trial showed that Skinuva™ Brite improved the appearance of hyperpigmentation in patients with hyperpigmentation that used the product twice a day for at least one month. Skinuva™ Brite was also shown to be tolerated very well with minimal irritation and redness.
Skinuva™ Brite does not include ingredients known to be potentially harmful to children, babies, or pregnant or nursing women when the product is used as directed.
Skinuva™ Brite can improve the appearance of dark spots and discoloration on the face and body. Skinuva™ Brite should be applied twice a day, morning and night to the affected areas. Sunscreen may be worn over Skinuva™ Brite.
Skinuva™ Brite can be purchased from physician offices that carry the Skinuva™ line, and also online at http://www.skinuva.com.
SOURCE Skinuva
![](https://rt.prnewswire.com/rt.gif?NewsItemId=UN64525&Transmission_Id=202003310800PR_NEWS_USPR_____UN64525&DateId=20200331)
Share this article